Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Amrinone: pharmacokinetics and pharmacodynamics.

J H Levy1, J M Bailey

  • 1Division of Cardiothoracic Anesthesiology, Emory University School of Medicine, Emory University Hospital, Atlanta, GA 30322.

Journal of Cardiothoracic Anesthesia
|December 1, 1989
PubMed
Summary

Amrinone, a phosphodiesterase 3 inhibitor, enhances cardiac contractility and vasodilation. Its long-acting profile and low side effect incidence offer a new therapeutic option for post-cardiac surgery ventricular dysfunction.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incorporating the concept of overtransfusion into hemovigilance monitoring: An expert-based definition and criteria from the International HIT-OVER Forum.

Transfusion·2024
Same author

Differential diagnoses for sepsis-induced disseminated intravascular coagulation: communication from the SSC of the ISTH.

Journal of thrombosis and haemostasis : JTH·2019
Same author

Derangement of the endothelial glycocalyx in sepsis.

Journal of thrombosis and haemostasis : JTH·2018
Same author

Sugammadex hypersensitivity and underlying mechanisms: a randomised study of healthy non-anaesthetised volunteers.

British journal of anaesthesia·2018
Same author

Use of factor concentrates for the management of perioperative bleeding: reply.

Journal of thrombosis and haemostasis : JTH·2018
Same author

Supplementary fibrinogen in the management of bleeding: re-evaluation of data from clinical trials.

British journal of anaesthesia·2018

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Amrinone selectively inhibits phosphodiesterase type 3 (PDE3) in cardiac and smooth muscle.
  • Ventricular dysfunction following cardiac surgery presents a significant therapeutic challenge.

Purpose of the Study:

  • To evaluate amrinone as a pharmacologic therapy for ventricular dysfunction post-cardiac surgery.
  • To assess the efficacy and safety profile of amrinone in this patient population.

Main Methods:

  • Intravenous administration of amrinone.
  • Monitoring of cardiac contractility and vascular tone.
  • Assessment of elimination half-life and side effect incidence.

Main Results:

  • Amrinone demonstrated increased cardiac contractility and vasodilation.

Related Experiment Videos

  • The drug has a long elimination half-life (2.6–4.1 hours) suitable for continuous infusion or bolus administration.
  • A low incidence of minor side effects was observed, with no significant thrombocytopenia in short-term use.

    • Conclusions:

    • Amrinone is a promising long-acting positive inotropic agent for managing ventricular dysfunction after cardiac surgery.
    • Its favorable pharmacokinetic and safety profile supports its use in this critical setting.